Squarepoint’s Prime Medicine PRME Stock Holding History

Squarepoint’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-88,029	Closed	-$325K	–	4918
2026 Q2	$325K	Sell	88,029 -6,037	-6%	-$20K	﹤0.01%	3746
2026 Q1	$327K	Sell	94,066 -123,976	-57%	-$472K	﹤0.01%	3642
2025 Q4	$757K	Buy	218,042 +178,441	+451%	+$794K	﹤0.01%	2852
2025 Q3	$219K	Buy	39,601 +3,775	+11%	+$15.3K	﹤0.01%	3885
2025 Q2	$88.5K	Buy	+35,826	New	+$55.2K	﹤0.01%	4201
2024 Q4	–	Sell	-124,369	Closed	-$481K	–	5405
2024 Q3	$481K	Buy	124,369 +60,908	+96%	+$282K	﹤0.01%	3125
2024 Q2	$326K	Buy	63,461 +3,895	+7%	+$23.6K	﹤0.01%	3381
2024 Q1	$417K	Sell	59,566 -11,957	-17%	-$90.7K	﹤0.01%	3181
2023 Q4	$634K	Buy	71,523 +56,033	+362%	+$432K	﹤0.01%	2839
2023 Q3	$148K	Buy	+15,490	New	+$201K	﹤0.01%	3494

Other funds holding PRME

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Squarepoint's PRME Position: Q3 2026 in Review

Squarepoint sold out of Prime Medicine (PRME) in Q3 2026, closing a stake of 88,029 shares — an estimated $325K sold.

Squarepoint first reported a position in PRME in Q3 2023 and held it in 10 quarters. The position peaked at $757K in Q4 2025. 75 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

Squarepoint reported no remaining Prime Medicine position as of Q3 2026 after selling out during the quarter.
Squarepoint sold 88,029 Prime Medicine shares in Q3 2026, an estimated $325K.
Squarepoint first reported a position in Prime Medicine in Q3 2023 and held it in 10 quarters.
Squarepoint's Prime Medicine position peaked at $757K in Q4 2025.
75 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.